OPSENS INC.

TO: *Autorité des marchés financiers* (as principal regulator)
Nova Scotia Securities Commission
Prince Edward Island Office of the Superintendent of Securities
Financial and Consumer Services Commission, New Brunswick
Office of the Superintendent of Securities Service, Newfoundland and Labrador
Ontario Securities Commission
The Manitoba Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Alberta Securities Commission
British Columbia Securities Commission

RE: Report of Voting Results Pursuant to Section 11.3 of Regulation 51-102 *respecting Continuous Disclosure Obligations* ("Regulation 51-102")

Following the special meeting of shareholders of OpSens Inc. ("OpSens") held on December 1, 2023 ("Meeting"), and in accordance with Section 11.3 of Regulation 51-102, we hereby advise you of the following voting results obtained at the Meeting:

Approval of the Arrangement

A special resolution, the full text of which is set forth in Appendix A to the management information circular of OpSens dated October 31, 2023 (the "Circular"), to approve an arrangement under the *Business Corporations Act* (Québec) involving the Corporation, Haemonetics Corporation and 9500-7704 Québec Inc., pursuant to which Haemonetics Corporation will acquire all of the issued and outstanding common shares in the capital of OpSens (the "Shares") for $2.90 in cash per Share, all as more particularly described in the Circular (which is available under the Corporation's profile on SEDAR+ at www.sedarplus.ca), was voted on by electronic ballot and approved as follows:

Votes For	% Votes For	Votes Against	% Votes Against
84,625,529	97.96%	1,762,576	2.04%

Dated December 1, 2023.

OPSENS INC.

By: *(s) Louis Laflamme*
Louis Laflamme
President and Chief Executive Officer